Targeted Lymphoma Cell Death by Novel Signal Transduction Modifications
Annual rept. 15 Jun 2008-14 Jun 2009
CALIFORNIA UNIV DAVIS
Pagination or Media Count:
The proposed research set to 1 create and characterize CD22-binding peptides that initiate signal transduction and apoptosis in non-Hodgkins lymphoma NHL, 2 optimize CD22-mediated signal transduction and lymphomacidal properties of ligand blocking anti-CD22 monoclonal antibodies mAbs and peptides with CD22-specific phosphatase inhibition and 3 correlate mAb-mediated and anti-CD22 peptide-mediated in vivo physiologic changes, efficacy, and tumor targeting using advanced immuno-positron emission topography i-PET and FDG-PET imaging technology. Since funding we have identified five peptides that are based on CDRs of anti-CD22 mAbs. Peptide 5 has been characterized and described in the annual report for year 1. Within year 2 we have identified several other peptides that are more effective that peptide 5 and we have begun to characterize their signaling, cytotoxic and apoptotic potential. In addition we have demonstrated that phosphatase inhibition augments the effectiveness of these peptides. Studies that will evaluate the effectiveness of these peptides in vivo are ongoing.
- Anatomy and Physiology
- Medicine and Medical Research